Management of Severe Hypertriglyceridemia

Introduction to Treatment

The American College of Cardiology recommends immediate fenofibrate therapy to prevent acute pancreatitis in patients with severe hypertriglyceridemia, followed by statin initiation once triglycerides fall below 500 mg/dL 1, 2

A triglyceride level of 544 mg/dL places the patient at significant risk for acute pancreatitis, requiring urgent pharmacologic intervention with fenofibrate as first-line therapy 1, 2
The American Heart Association suggests that fenofibrate will reduce triglycerides by 30-50%, bringing levels below the pancreatitis risk threshold, which is a Class IIa recommendation with Level B-R evidence for patients with severe hypertriglyceridemia (≥500 mg/dL) and ASCVD risk ≥7.5% 1, 2

The American College of Cardiology recommends restricting total dietary fat to 20-25% of total daily calories for severe hypertriglyceridemia 3, 5
Eliminating all added sugars completely is advised, as sugar intake directly increases hepatic triglyceride production 3, 5
Complete abstinence from alcohol is mandatory, as even 1 ounce per day increases triglycerides by 5-10% and can precipitate hypertriglyceridemic pancreatitis at this level 3, 5
Targeting 5-10% body weight reduction is recommended, which produces a 20% decrease in triglycerides and is the single most effective lifestyle intervention 3, 5

Once triglycerides fall below 500 mg/dL with fenofibrate, the American College of Cardiology recommends initiating moderate-to-high intensity statin therapy to address LDL-C and reduce cardiovascular risk 3, 5
Adding prescription omega-3 fatty acids (icosapent ethyl 2-4 g/day) is considered if triglycerides remain elevated after fenofibrate and lifestyle optimization 1, 2, 3

The American College of Cardiology suggests considering conditions specific to women, such as premature menopause and history of pregnancy-associated disorders, when discussing statin therapy 1, 2, 4
Continuing moderate- or high-intensity statin therapy if well-tolerated is recommended even after age 75 in patients with diabetes or established ASCVD 5

Reassessing fasting lipid panel in 4-8 weeks after initiating fenofibrate is recommended 5
Monitoring transaminases (AST/ALT) at baseline and periodically, as well as checking creatine kinase and monitoring for muscle symptoms when combining therapies, is advised 3, 5

The primary goal is to reduce triglycerides to <500 mg/dL rapidly to prevent acute pancreatitis 3, 5
The secondary goal is to achieve non-HDL-C <130 mg/dL once triglycerides are controlled 3, 5
The tertiary goal is LDL-C reduction based on cardiovascular risk assessment once triglycerides are stabilized 5